Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17701138 | 1.00 | FOLH1 (0.54) | FOLH1DGAT1 | |
| SCHEMBL17599927 | 0.90 | FOLH1 (0.59) | FOLH1DGAT1 | |
| SCHEMBL17599928 | 0.90 | FOLH1 (0.59) | FOLH1DGAT1 | |
| SCHEMBL17599924 | 0.90 | DGAT1 (0.53) | FOLH1DGAT1 | |
| SCHEMBL17599926 | 0.90 | DGAT1 (0.53) | FOLH1DGAT1 | |
| SCHEMBL17701134 | 0.89 | FOLH1 (0.50) | FOLH1DGAT1 | |
| SCHEMBL17701135 | 0.89 | FOLH1 (0.50) | FOLH1DGAT1 | |
| SCHEMBL17599916 | 0.87 | FOLH1 (0.50) | FOLH1DGAT1 | |
| SCHEMBL17599918 | 0.87 | FOLH1 (0.50) | FOLH1DGAT1 | |
| SCHEMBL17615122 | 0.86 | DGAT1 (0.49) | FOLH1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396621-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2022-12-15 | — | — | US | disclosed |
| US-11377496-B2 | Targeting agent antibody conjugates and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3721902-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | The Scripps Research Institute (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-2968552-B1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20190315863-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-17 | — | — | US | disclosed |
| US-10351626-B2 | Targeting agent antibody conjugates and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170002076-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-01-05 | — | — | US | disclosed |
| US-20160115232-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351626-B2 | Targeting agent antibody conjugates and uses thereof | FCGR2A, CD22, FCGR3B | FOLH1 340/4885DGAT1 3169/4885 |
| US-20220396621-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | CD22, FCGR2A, CD47 | FOLH1 226/4885DGAT1 2892/4885 |
| US-20190315863-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | FCGR2A, CD22, FCGR3B | FOLH1 340/4885DGAT1 3169/4885 |
| US-20170002076-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | FCGR2A, CD22, FCGR3B | FOLH1 340/4885DGAT1 3169/4885 |
| US-20160115232-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | FCGR2A, CD22, FCGR3B | FOLH1 340/4885DGAT1 3169/4885 |
| US-11377496-B2 | Targeting agent antibody conjugates and uses thereof | FCGR2A, CD22, FCGR3B | FOLH1 340/4885DGAT1 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.